BACKGROUND: To date, no targeted therapy has been approved for nasopharyngeal carcinoma (NPC), and this underscores the need for an in-depth understanding of clinically relevant genomic alterations (CRGAs). METHODS: Comprehensive genomic profiling was performed for 190 NPC patients, including 20 patients with nasopharyngeal adenocarcinoma (NPAC), 62 patients with nasopharyngeal squamous cell carcinoma (NPSCC), and 108 patients with nasopharyngeal undifferentiated carcinoma (NPUC). The associations of genes and pathways with subtypes, Epstein-Barr virus (EBV) infections, and the tumor mutation burden (TMB) were statistically evaluated. RESULTS: Although the overall rates of genomic alterations were similar, the 3 NPC subtypes exhibited different mutational landscapes. Notably, mutations in a proven-treatable target gene, isocitrate dehydrogenase 2 (IDH2), were significantly associated with NPUC but not with NPAC or NPSCC. The top 5 ranked CRGAs included CDKN2A (29%), IDH2 (16%), SMARCB1 (7%), PIK3CA (6%), and NF1 (5%) in NPUC; CDKN2A (27%), PIK3CA (23%), FBXW7 (11%), PTEN (11%), and EGFR (8%) in NPSCC; and CDKN2A (20%), KRAS (15%), CCND1 (10%), MAP3K1 (10%), and NOTCH1 (10%) in NPAC. The incidence of EBV infections significantly correlated with the subtypes and with TP53, CDKN2A, and CDKN2B. The TMB status correlated with the subtypes and with LRP1B, FBXW7, and PIK3CA mutations as well as DNA repair, phosphoinositide 3-kinase/mammalian target of rapamycin, and mitogenactivated protein kinase pathways. CONCLUSIONS: These results indicate that different NPC subtypes harbor different CRGAs. Both EBV infections and the TMB are associated with the NPC subtypes as well as the alterations of individual genes and pathways. The high frequency of IDH2 mutations in NPUC may facilitate potential targeted therapy and will ultimately point to new therapeutic strategies.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a distinct type of head and neck cancer arising from the epithelial lining of the nasopharynx that has unique epidemiological characteristics, including regional, racial, and familial aggregation. 1 Although its incidence rates are as low as less than 1 per 100,000 in most of the world, its occurrence is remarkably high in China, Southeast Asia, Northern Africa, and Alaska, where the rates are 25-fold higher or more. 2, 3 Significant familial clustering has also been observed in these areas. 4 In addition, an Epstein-Barr virus (EBV) infection is frequently found in patients diagnosed with NPC. 5 Moreover, NPC has a higher incidence in males versus females with a sex ratio of approximately 2.3:1. 6 The annual incidence of NPC has increased dramatically: it resulted in 65,000 deaths globally as of 2010 versus 45,000 deaths in 1990. 7 The main current treatments include surgery, chemotherapy, radiotherapy, and their combinations. 8 Although early-stage NPC is highly sensitive to radiotherapy, a majority of patients present at locally advanced stages and typically require various modes of combined chemoradiotherapy (CRT). 9 Despite initial responses, most patients with advanced NPC develop intolerable toxicity from CRT, and their tumors acquire resistance to CRT. 10 The median survival time for advanced NPC patients is only 5 to 11 months. 11 Because of the lower toxicity and CRT resistance, targeted therapy has increasingly been used whenever possible for many common malignancies, including breast, colorectal, lung, and other solid tumors as well as lymphoma, leukemia, and multiple myeloma. Unfortunately, because of the lack of understanding of its molecular pathogenesis, targeted therapies for NPC are relatively underdeveloped. In the past 10 years, only a few clinical trials targeting epidermal growth factor receptor 12 and vascular endothelial growth factor receptor 11 have been studied in NPC patients, but the rates of overall and disease-free survival in these trials have been unsatisfactory. [10] [11] [12] A phase 1 clinical trial using a programmed death 1 inhibitor to treat recurrent or metastatic NPC showed an overall response rate of 22% among 27 heavily treated NPC patients, and the median duration of response was 10.8 months. 13 The new approaches to treating NPC, including targeted therapy and immunotherapy, highlight the need for the identification of new therapeutic targets by techniques such as comprehensive genomic profiling.
NPC histopathology can be divided into 3 major types: keratinizing or nonkeratinizing squamous cell carcinoma (nasopharyngeal squamous cell carcinoma [NPSCC]), poorly or undifferentiated carcinoma (nasopharyngeal undifferentiated carcinoma [NPUC]), and nasopharyngeal adenocarcinoma (NPAC). Malignant lymphomas and sarcomas account for less than 5% of all nasopharyngeal cancers. 1, 14 Although genomic alterations (GAs) have been studied with sequencing or singlenucleotide polymorphism arrays in individual types of NPC, 15 the molecular characteristics of all types of NPC have not been rigorously reported. In this study, a series of 190 NPC cases, including 20 NPAC cases, 62 NPSCC cases, and 108 NPUC cases, were subjected to a hybrid capture-based comprehensive genomic profiling assay to identify potential therapy targets. The mutational signatures and their biological pathways were interrogated for their association with the 3 NPC subtypes. The EBV infection status and the tumor mutation burden (TMB) as well as their impact on therapy selection were also investigated for these NPC subtypes.
MATERIALS AND METHODS

Patient and Sequencing
In total, 190 NPC cases were collected; they included 20 NPAC cases, 62 NPSCC cases, and 108 NPUC cases. Formalin-fixed, paraffin-embedded tissue sections were used, and at least 50 ng of DNA was extracted from each sample. As previously prescribed, 16 all the coding exons of 315 cancer-related genes and selected introns of 19 common genes rearranged in cancer were captured and sequenced with a mean coverage of 650 with an Illumina HiSeq2500 instrument in a Clinical Laboratory Improvement Amendments-certified, College of American Pathologists-accredited laboratory. The classes of GAs, including base substitutions, small insertions and deletions (indels), gene amplifications and deletions, fusions, and rearrangements, were subsequently analyzed. As previously described, 16 bioinformatic processes were used to analyze the next-generation sequencing data. Basesubstitution detection was performed with a Bayesian methodology, which detected somatic mutations at a low mutant allele frequency and with increased sensitivity for mutations at hotspot sites through the incorporation of tissue-specific prior expectations, including the Catalogue of Somatic Mutations in Cancer database. Reads with a mapping quality lower than 20 were discarded. De novo local assembly was performed with the de Bruijn approach to detect indels. After read pairs were collected in each targeted region, the statistical support for competing haplotypes was evaluated, and candidate indels were aligned against the reference genome hg19. A comparison with process-matched normal control samples to detect gene focal amplifications and homozygous deletions and an analysis of chimeric read pairs to identify gene fusions and rearrangements were performed. Clinically relevant genomic alterations (CRGAs) were further defined as those GAs that were druggable in current treatments or clinical trials. Approval for this study, including a waiver of informed consent and a HIPAA waiver of authorization, was obtained from the Western Institutional Review Board (Protocol No. 20152817).
EBV and TMB
An EBV infection was detected via the sequencing of the virus-specific genomic region and was further quantified as reads per million bases. 17 The cases with more than 10 reads per million were considered to have an infection. TMB was calculated with a minimum of 1.2 Mb of extracted DNA and was reported as the number of somatic coding short variant mutations per megabase. 18 
Statistical Analysis
Associations of the 3 NPC subtypes with gene or pathway mutations were assessed with Fisher's exact test; the level of significance was set at P .05. A pathway was considered to be mutated if it carried any mutation for its component gene. Coefficients of variation of the mutational frequencies of genes were applied to order their differences across the NPC subtypes, and the top 20 genes were highlighted. To compare mutational landscapes between different subtypes, a normalization step was first applied among the alternation frequencies of different genes before an analysis of variance (ANOVA). Associations of EBV infections with genes or pathways and NPC subtypes were estimated with a subtype-adjusted logistic regression; for TMB, a linear regression model was used. The Benjamini-Hochberg method 19 was used to adjust P values for all the tests when multiple testing was concerned. All of the statistical tests were performed with R statistical tools (https://www.r-project.org/).
RESULTS
Clinical Information
The clinical characteristics of 190 NPC patients (including 20 NPAC patients, 62 NPSCC patients, and 108 NPUC patients) are summarized in Table 1 . The median age of all NPC patients was 53 years (range, 8-90 years). No significant differences in age or subtype were detected (P 5 .44 [ANOVA test]). A male predominance in the incidence of NPC was clearly observed in our study with a male-tofemale ratio of approximately 2.1 (128 males and 62 females); this was in agreement with previous reports. 6 However, this ratio did not correlate with the 3 subtypes (P 5 .45 [Fisher's exact test]). The primary collection sites for NPC included the nasopharynx, head and neck, and paranasal sinuses as well as the nasal cavity, whereas the metastatic sites mainly included the liver and lymph nodes.
Landscapes of Somatic Genomic Alternations Across the 3 NPC Subtypes
Overall, there were 723 GAs identified in the 190 NPC cases (3.8 GAs per tumor); they included 320 CRGAs with a mean of 1.7 CRGAs per tumor (Supporting Table  1 [see online supporting information]). The GAs were similarly distributed among the 3 subtypes with 74 GAs in NPAC cases (3.7 GAs per sample), 257 GAs in NPSCC cases (4.1 GAs per sample), and 395 GAs in NPUC cases (3.7 GAs per sample). The top 5 ranked CRGAs involved a wide variety of base substitutions, indels, copy-number changes, and rare gene fusions ( Fig.  1A ): CDKN2A (29%), isocitrate dehydrogenase 2 (IDH2; 16%), SMARCB1 (7%), PIK3CA (6%), and NF1 (5%) in NPUC; CDKN2A (27%), PIK3CA (23%), FBXW7 (11%), PTEN (11%), and EGFR (8%) in NPSCC; and CDKN2A (20%), KRAS (15%), CCND1 (10%), MAP3K1 (10%), and NOTCH1 (10%) in NPAC. Notably, each subtype appeared to harbor a unique combination of GAs (Fig. 1A-C) ; this was highlighted by the top 20 differentially altered genes (Fig. 2) . Such differences were further assessed to be significant (P 5 7.9 3 10
Notably, IDH2 was the most significantly altered gene across the 3 NPC subtypes (15.7% in NPUC and 0% in NPAC and NPSCC) with an adjusted P value of .006 (Benjamini-Hochberg method). Seventeen mutations of IDH2 at R172 were identified in 17 NPUC patients; they included R172S (n 5 8), R172G (n 5 4), R172T (n 5 4), and R172M (n 5 1). R172 is a mutation hotspot recurrently reported in acute myeloid leukemia, gliomas, and others. [20] [21] [22] An IDH2 R172 residue is located in the active site of the enzyme, and the change at 
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Cancer September 15, 2017 this residue confers enzymatic neo-activity that leads to abnormal production of the D form of 2-hydroxyglutarate instead of a-ketoglutarate. 23 2-Hydroxyglutarate competes with a-ketoglutarate to inhibit a-ketoglutarate-dependent dioxygenases, which are involved in a number of cellular processes, including cell differentiation 24, 25 and the hypoxia response. 26, 27 IDH2 mutations at R172 have been reported to produce 2-hydroxyglutarate, which inhibits the DNA demethylase Tet2. 27 No mutation in TET2 or other genes in the pathway was detected in the NPC patients. The most often co-occurring gene alterations were found in TP53 (13 of 17 IDH2-mutant samples; Fig. 3 ).
In addition, GAs of MAP3K1 (10%), APC (15%), KRAS (15%), SMARCB1 (10%), and ARID1A (15%) occurred in NPAC more frequently than in the other 2 subtypes, whereas GAs associated with PTEN (11.3%), FBXW7 (11.3%), MLL2 (12.9%), and PIK3CA (22.6%) were highest in NPSCC. Although these differences were insignificant after multiple test adjustments, most mutations, excluding ARID1A, APC, and MLL2, were identified as potential drug targets. These inform potentially different targeted treatments. Pathways that harbored at least 3 genetic alternations in our cohort and have been demonstrated to be NPC-associated in the literature include DNA repair, phosphoinositide 3-kinase (PI3K)/ mammalian target of rapamycin (mTOR), and mitogenactivated protein kinase (MAPK) pathways. Nevertheless, none of them significantly correlated with the subtypes after adjustments for false discovery.
EBV Infections Were Associated With the 3 NPC Subtypes
The total number of EBV-infected patients in the overall NPC cohort was 72 (infection rate, 37.9%). The EBV detection rates were significantly correlated with the 3 subtypes (P 5 .0008 [Fisher's exact test]): 48% of NPUC cases, 29% of NPSCC cases, and 10% of NPAC cases (Fig. 4A) . However, in the infected patients, the numbers of reads per million for EBV infections were not significantly different across the subtypes (P 5 .88 [ANOVA test]; Fig. 4B) . Interestingly, the associations between an EBV infection and the GAs of TP53, CDKN2A, CDKN2B, and PIK3CA were found to be significant in the whole NPC cohort; the adjusted P values were . Because an EBV infection was significantly correlated with NPC subtypes, its association with the Figure 2 . Genomic alternations in the overall cohort of NPC patients. The top 15 differentially altered genes and the mutation frequencies in NPAC, NPSCC, and NPUC are shown. The genes were selected and ordered by their coefficients of variation (see the Materials and Methods section for details) in the overall cohort of NPC patients. NPAC indicates nasopharyngeal adenocarcinoma; NPC, nasopharyngeal carcinoma; NPSCC, nasopharyngeal squamous cell carcinoma; NPUC, nasopharyngeal undifferentiated carcinoma.
aforementioned GAs was adjusted for the subtype via logistic regression. TP53 (adjusted P 5 .001), CDKN2A (adjusted P 5.05), and CDKN2B (adjusted P 5 .05) remained significantly associated with an EBV infection, whereas PIK3CA became slightly insignificant (adjusted P 5 .06). Similar analyses for the 3 pathways revealed that all of them were significantly correlated with an EBV infection with the subtype being considered; the adjusted P values were .0005, .003, and .002, respectively (Fig. 5A-C) . Altogether, there were significant associations of EBV infections with specific GAs and subtypes of NPC.
TMB
The association of TMB with NPC subtypes was shown to be slightly significant: 5.42 for NPAC, 7.07 for NPSCC, and 4.38 for NPUC (P 5 .04 [ANOVA test]). The frequency of NPCs harboring more than 10 mutations per megabase was 15% for NPSCC, 10% for NPAC, and 5% for NPUC. An EBV infection was associated with a high TMB with near significance (P 5 .07 [ANOVA test]). LRP1B GAs were significantly associated with a high TMB (adjusted P 5 2.35 310 -6 ), and this association was enhanced after subtype adjustments . Similarly, mutations affecting FBXW7 (adjusted P 5 .004) and PIK3CA (adjusted P 5 2.9 3 10 -4 ) were also associated with higher TMB levels. DNA repair (adjusted P 5 .009), PI3K/mTOR (adjusted P 5 .002), and MAPK pathways (adjusted P 5 .0003) showed strong and significant associations with the TMB status independently of the NPC subtypes, and they remained significant when the subtypes were included in the analysis with adjusted P values of .004, .005, and .0001, respectively.
DISCUSSION
In this study, comprehensive genomic profiling was performed for 190 NPC cases, including 20 NPAC cases, 62 NPSCC cases, and 108 NPUC cases. No significant differences in the clinical features were found across patients within the 3 subtypes. Furthermore, no obvious differences were identified in their GA frequencies. However, significant differences in the individual genomic landscapes were detected in the different NPC subtypes, and this suggests that different genetic mechanisms underlie the causation and progression of these tumors and that these subset-specific individual GAs could have a significant impact on potential treatment strategies.
Importantly, in this study, CRGAs were annotated and interrogated for their potential impact on NPC treatments. The overall cohort harbored a CRGA rate as high as 1.7 per tumor. Notably, CRGAs of MAP3K1 and KRAS occurred at a rate of 10% or higher in NPAC but less frequently in the other 2 subtypes. Similar observations were made for CRGAs of PTEN, FBXW7, and PIK3CA in NPSCC patients. Altogether, optional targets of potential treatments were implied for the different subtypes.
IDH2 mutations were significantly enriched in NPUC (16%) according to the 190 samples tested but not in NPAC or NPSCC. IDH2 encodes a member protein of the IDH family that catalyzes the oxidative decarboxylation of isocitrate to produce carbon dioxide and aketoglutarate. Recurrent mutations in IDH2 have been reported in gliomas, acute myeloid leukemia, and other cancer types. 20, 21, 28 Patients carrying these mutations may have poor clinical outcomes and few effective treatment options. 29, 30 IDH mutations in gliomas are mostly found in lower grade diffuse gliomas, and they are associated with more complete surgical resection and with a better response to radiation treatment. 31 Enasidenib (AG-221) is a first-in-class oral, potent, reversible, selective inhibitor of mutated IDH2; it has entered clinical trials and demonstrated clinical activity in patients with advanced blood cancers. 32 In a phase 1/2 study of the IDH2 mutant inhibitor enasidenib for the treatment of patients with IDH2 mutation-positive advanced hematologic malignancies (particularly acute myeloid leukemia), the overall response rate was 41% among 198 IDH2-mutated acute myeloid leukemia patients, and the complete remission rate was 17%. 33 In another clinical trial of enasidenib treating 17 myelodysplastic syndrome patients with IDH2 mutations, the overall response rate was 59%. 34 In addition, am IDH2 mutation may predict sensitivity to DNA methyltransferase inhibitors such as the Food and Drug Administration-approved therapies azacitidine and decitabine. Acute myeloid leukemia patients with a mutation in IDH1 or IDH2 have been reported to achieve a much better rate of overall response to azacitidine or decitabine. 35 Unlike GA profiling of blood cancer patients, no co-occurring mutations of TET2, ASXL1, or SRSF2 were found in tested IDH2-mutated NPC patients. The trial of enasidenib is ongoing for solid tumor patients with IDH2 mutations. 36 Recently, an in vitro study identified dasatinib hypersensitivity in IDHmutated intrahepatic cholangiocarcinoma cell lines with an SRC dependency. 37 The promising clinical data for enasidenib as well as preclinical evidence for dasatinib shed the light of potential treatment paradigms for NPUC. Altogether, the incorporation of IDH2 mutation detection into the standard workup for NPUC molecular testing could be considered to tailor treatment by the molecular profile and to facilitate the early identification of patients who may benefit from targeted therapies.
NPC has been definitively characterized as an EBVassociated epithelial malignancy. 38 However, to the best of our knowledge, EBV infections have seldom been studied with respect to NPC subtypes and their respective CRGAs. In our cohort, the EBV infection status was highest in NPUC and lowest in NPAC. This indicates that EBV infections in the tumorigenic process of NPC could have different biological impacts among its subtypes. Furthermore, it has been reported that an EBV infection by itself cannot transform nasopharyngeal epithelial cells, and additional genetic and epigenetic abnormalities are needed to initiate the transformation. 39, 40 Thus, in the current study, a series of association tests were designed with the EBV infection status in a comparison with GAs in all NPC cases and subtypes as a secondary independent variable in a logistic regression model. Remarkably, GAs of TP53, CDKN2A, and CDKN2B were significantly associated with EBV whether the subtype was taken into consideration or not. This observation has also been made for human papillomavirus-infected head and neck squamous cell carcinoma: certain GAs (eg, PIK3CA) are enriched in human papillomavirus-positive head and neck squamous cell carcinoma. [41] [42] [43] When alternations in DNA repair, PI3K/mTOR, or MAPK pathways are considered, an EBV infection is also significantly associated with them for the subtype. Taken together, these observations suggest that an EBV infection may have different impacts on the tumorigenesis of the NPC subtypes, with different interactions with the genomic aberrations involving TP53, CDKN2A, and CDKN2B as well as DNA repair, PI3K/mTOR, or MAPK pathways.
TMB was measured as a reflection of the somatic mutational rate per tumor. As previously reported, the value could be extrapolated to the burden measured by wholeexome sequencing and thus potentially linked to predicted benefits from immune checkpoint inhibitors. 18 A high TMB has been correlated with improved efficacy of immunotherapy in melanoma and lung cancer. 44, 45 TMB, measured by a cancer gene panel, also successfully predicted a greater likelihood of response to cancer immunotherapies in locally advanced or metastatic bladder patients treated with atezolizumab (anti-programmed death ligand 1; Genentech/Roche). 13, 46 In a phase I clinical trial, more than onefifth of 27 advanced NPC patients with positive programmed death ligand 1 expression responded to a programmed death 1 inhibitor, and another 15 patients showed stable diseases. 13 In our study, the degrees of TMB were moderately associated with the NPC subtypes. This was consistent with the aforementioned finding that the overall mutational landscapes were significantly different across the subtypes. Thus, it is likely that the responses of the 3 NPC subtypes to immune checkpoint inhibitor therapies could be different because of the relative differences in neo-antigen production by the different tumor types. Significantly, the mutations of LRP1B, FBXW7, and PIK3CA were associated with TMB independently of the NPC subtype. Similar observations were also made when DNA repair, PI3K/mTOR, and MAPK pathways were evaluated. Notably, truncations or a loss of the LRP1B gene were found to be highly associated with the TMB status (adjusted P 5 6.45 3 10 -6 ). LRP1B encodes a lipid transporter and is one of the top 10 genes altered in cancers. 47 The higher TMB score observed in LRP1B-mutated NPC could potentially be explained by this gene's large size and location near the FRA2F fragile site 48 as an association event. However, the deletion of LRP1B has also been reported to be involved in the emergence of resistance to chemotherapy in highgrade serous ovarian cancers. 49 Moreover, it was considered as a tumor suppressor to inhibit cell migration; this was supported by both in vitro 50 and in vivo results. 51 Therefore, the testing of anomalies of LRP1B as potential biomarkers for clinical application to NPC warrants further investigation.
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